 Ryan Lanning
Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 5 | 2026 | 759 | 0.980 |
Why?
| | Skin Neoplasms | 5 | 2026 | 850 | 0.890 |
Why?
| | Sarcoma | 1 | 2024 | 204 | 0.690 |
Why?
| | Immunotherapy | 1 | 2024 | 667 | 0.580 |
Why?
| | Trastuzumab | 1 | 2015 | 117 | 0.410 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1150 | 0.350 |
Why?
| | Radiotherapy, Image-Guided | 2 | 2025 | 39 | 0.350 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 2 | 2025 | 149 | 0.330 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2024 | 223 | 0.330 |
Why?
| | Antineoplastic Agents | 3 | 2019 | 2207 | 0.300 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2017 | 644 | 0.270 |
Why?
| | Laryngeal Neoplasms | 2 | 2017 | 36 | 0.250 |
Why?
| | Medical Oncology | 2 | 2026 | 338 | 0.230 |
Why?
| | Microscopy | 2 | 2022 | 148 | 0.230 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2025 | 32 | 0.230 |
Why?
| | Acoustics | 1 | 2025 | 48 | 0.220 |
Why?
| | Carcinoma | 2 | 2017 | 224 | 0.220 |
Why?
| | Hutchinson's Melanotic Freckle | 1 | 2024 | 3 | 0.210 |
Why?
| | Breast Neoplasms | 3 | 2015 | 2373 | 0.210 |
Why?
| | Combined Modality Therapy | 2 | 2024 | 1269 | 0.190 |
Why?
| | Contrast Media | 2 | 2025 | 500 | 0.190 |
Why?
| | Neoplasms | 6 | 2022 | 2897 | 0.170 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 562 | 0.170 |
Why?
| | Mammary Neoplasms, Experimental | 2 | 2019 | 62 | 0.160 |
Why?
| | Glottis | 2 | 2017 | 20 | 0.160 |
Why?
| | Drug Carriers | 1 | 2019 | 134 | 0.140 |
Why?
| | Chemoradiotherapy | 2 | 2017 | 239 | 0.130 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2017 | 21 | 0.130 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 9 | 0.130 |
Why?
| | Oxygen | 4 | 2022 | 986 | 0.130 |
Why?
| | Meningioma | 1 | 2018 | 88 | 0.130 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 19 | 0.130 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 95 | 0.130 |
Why?
| | Cisplatin | 1 | 2019 | 345 | 0.130 |
Why?
| | Nose Neoplasms | 1 | 2017 | 21 | 0.130 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 17 | 0.130 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 29 | 0.130 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 427 | 0.130 |
Why?
| | Dexamethasone | 1 | 2019 | 366 | 0.120 |
Why?
| | Ear Neoplasms | 1 | 2016 | 10 | 0.120 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2016 | 16 | 0.120 |
Why?
| | Misonidazole | 1 | 2016 | 1 | 0.120 |
Why?
| | Ear Canal | 1 | 2016 | 15 | 0.120 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2016 | 56 | 0.120 |
Why?
| | Brachytherapy | 1 | 2016 | 133 | 0.110 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2016 | 142 | 0.110 |
Why?
| | Humans | 22 | 2026 | 145491 | 0.110 |
Why?
| | Lymphatic Metastasis | 1 | 2015 | 335 | 0.100 |
Why?
| | Quantum Dots | 1 | 2013 | 37 | 0.100 |
Why?
| | Protein Array Analysis | 1 | 2013 | 56 | 0.100 |
Why?
| | Mastectomy | 1 | 2015 | 181 | 0.100 |
Why?
| | Disease-Free Survival | 1 | 2015 | 771 | 0.090 |
Why?
| | Nanoparticles | 1 | 2019 | 519 | 0.090 |
Why?
| | Optics and Photonics | 2 | 2003 | 39 | 0.090 |
Why?
| | Propensity Score | 3 | 2017 | 376 | 0.080 |
Why?
| | Spectroscopy, Near-Infrared | 2 | 2002 | 70 | 0.080 |
Why?
| | Neoplasm Metastasis | 3 | 2019 | 691 | 0.080 |
Why?
| | Aged | 8 | 2018 | 26125 | 0.080 |
Why?
| | Scattering, Radiation | 3 | 2025 | 99 | 0.080 |
Why?
| | Fluorescence Recovery After Photobleaching | 1 | 2009 | 19 | 0.070 |
Why?
| | Cell Physiological Phenomena | 1 | 2009 | 19 | 0.070 |
Why?
| | Extracellular Fluid | 1 | 2009 | 38 | 0.070 |
Why?
| | Male | 10 | 2025 | 72817 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1332 | 0.070 |
Why?
| | Female | 16 | 2025 | 78763 | 0.070 |
Why?
| | Middle Aged | 9 | 2018 | 36176 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2017 | 8326 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1039 | 0.070 |
Why?
| | Neoplasm Staging | 2 | 2024 | 1468 | 0.060 |
Why?
| | Palliative Care | 1 | 2015 | 1017 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 342 | 0.060 |
Why?
| | Young Adult | 4 | 2017 | 14192 | 0.060 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 737 | 0.060 |
Why?
| | Blood Vessels | 1 | 2007 | 167 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2016 | 288 | 0.060 |
Why?
| | X-Rays | 1 | 2025 | 28 | 0.060 |
Why?
| | Volatilization | 1 | 2025 | 53 | 0.060 |
Why?
| | Imaging, Three-Dimensional | 1 | 2009 | 587 | 0.060 |
Why?
| | Fetal Blood | 1 | 2007 | 325 | 0.060 |
Why?
| | Microbubbles | 1 | 2025 | 53 | 0.060 |
Why?
| | Adult | 7 | 2018 | 40707 | 0.050 |
Why?
| | Metal Nanoparticles | 1 | 2025 | 82 | 0.050 |
Why?
| | Gold | 1 | 2025 | 116 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 974 | 0.050 |
Why?
| | Hematopoietic Stem Cells | 1 | 2007 | 419 | 0.050 |
Why?
| | Prognosis | 2 | 2026 | 4323 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1544 | 0.050 |
Why?
| | Spectrophotometry | 1 | 2002 | 56 | 0.050 |
Why?
| | Angiotensins | 1 | 2022 | 8 | 0.050 |
Why?
| | Receptors, Angiotensin | 1 | 2022 | 11 | 0.050 |
Why?
| | Losartan | 1 | 2022 | 13 | 0.050 |
Why?
| | Temperature | 1 | 2025 | 681 | 0.040 |
Why?
| | Survival Rate | 2 | 2017 | 2093 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2007 | 866 | 0.040 |
Why?
| | Databases, Factual | 2 | 2017 | 1500 | 0.040 |
Why?
| | Mice | 5 | 2022 | 18338 | 0.040 |
Why?
| | Neoplasm Transplantation | 3 | 2009 | 246 | 0.040 |
Why?
| | Time Factors | 5 | 2017 | 7171 | 0.040 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2021 | 117 | 0.040 |
Why?
| | Mammography | 1 | 2002 | 166 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2003 | 3897 | 0.040 |
Why?
| | Animals | 8 | 2022 | 38141 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2021 | 173 | 0.040 |
Why?
| | Diffusion | 2 | 2011 | 124 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1896 | 0.040 |
Why?
| | Photons | 1 | 2000 | 73 | 0.040 |
Why?
| | Prospective Studies | 2 | 2025 | 8039 | 0.040 |
Why?
| | Micelles | 1 | 2019 | 40 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2026 | 2355 | 0.030 |
Why?
| | Mice, Nude | 1 | 2019 | 678 | 0.030 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2017 | 44 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5992 | 0.030 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 38 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 51 | 0.030 |
Why?
| | Organs at Risk | 1 | 2016 | 37 | 0.030 |
Why?
| | Tumor Hypoxia | 1 | 2016 | 7 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1261 | 0.030 |
Why?
| | Radiometry | 1 | 2016 | 56 | 0.030 |
Why?
| | Radiotherapy, Conformal | 1 | 2016 | 74 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2003 | 923 | 0.030 |
Why?
| | Radiation Protection | 1 | 2016 | 41 | 0.030 |
Why?
| | Cochlea | 1 | 2016 | 73 | 0.030 |
Why?
| | Insurance Coverage | 1 | 2017 | 243 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2016 | 207 | 0.030 |
Why?
| | United States | 3 | 2017 | 16115 | 0.030 |
Why?
| | Hypoxia | 1 | 2022 | 1199 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2016 | 343 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2017 | 502 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 466 | 0.030 |
Why?
| | Boronic Acids | 1 | 2013 | 36 | 0.020 |
Why?
| | Rats, Inbred F344 | 2 | 2003 | 268 | 0.020 |
Why?
| | Rats | 3 | 2009 | 5581 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1327 | 0.020 |
Why?
| | Infant | 2 | 2017 | 10064 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 563 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2018 | 11831 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2130 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2013 | 335 | 0.020 |
Why?
| | Risk Factors | 1 | 2026 | 10874 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2021 | 1329 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3537 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2862 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2013 | 382 | 0.020 |
Why?
| | Lymphography | 1 | 2009 | 13 | 0.020 |
Why?
| | Subcutaneous Tissue | 1 | 2009 | 26 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1965 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 169 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2018 | 17269 | 0.020 |
Why?
| | Chickens | 1 | 2009 | 184 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 302 | 0.020 |
Why?
| | Collagen Type I | 1 | 2009 | 143 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2017 | 1101 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2009 | 190 | 0.020 |
Why?
| | Image Enhancement | 1 | 2009 | 200 | 0.020 |
Why?
| | Microvessels | 1 | 2009 | 98 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 532 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2007 | 87 | 0.020 |
Why?
| | Adolescent | 2 | 2017 | 22485 | 0.020 |
Why?
| | Hyaluronic Acid | 1 | 2009 | 225 | 0.020 |
Why?
| | Cell Separation | 1 | 2007 | 304 | 0.020 |
Why?
| | Glioblastoma | 1 | 2009 | 353 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2772 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2017 | 6437 | 0.010 |
Why?
| | Methylene Blue | 1 | 2002 | 24 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4559 | 0.010 |
Why?
| | Indocyanine Green | 1 | 2002 | 42 | 0.010 |
Why?
| | Coloring Agents | 1 | 2002 | 91 | 0.010 |
Why?
| | Fibroadenoma | 1 | 2002 | 2 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2823 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11837 | 0.010 |
Why?
| | Premenopause | 1 | 2002 | 123 | 0.010 |
Why?
| | Algorithms | 1 | 2009 | 1855 | 0.010 |
Why?
| | Breast | 1 | 2002 | 157 | 0.010 |
Why?
| | Radiography | 1 | 2002 | 852 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2007 | 2499 | 0.010 |
Why?
| | Kinetics | 1 | 2002 | 1605 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 821 | 0.010 |
Why?
| | Water | 1 | 2002 | 468 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2002 | 579 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2002 | 529 | 0.010 |
Why?
| | Hemoglobins | 1 | 2000 | 386 | 0.010 |
Why?
| | Child | 1 | 2017 | 22680 | 0.010 |
Why?
|
|
Lanning's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|